Objective — to evaluate the effectiveness of posterizan combined with the most effective minimally invasive surgical techniques in the complex treatment of patients with hemorrhoid disease grade II—III. Material and methods. A prospective, randomized controlled trial included 2 comparable groups. There were 100 patients with hemorrhoid disease grade II—III in each group. Fifty patients underwent dearterialization followed by mucosal lifting, other 50 patients — sclerotherapy of hemorrhoids. Topical administration of posterisan in addition to minimally invasive treatment was applied in the first group: rectal ointment twice a day within 2 days after surgery, posterisan suppositories twice a day after 2 days within 2 subsequent weeks. Posterisan was not used in the control group. Results. There were better outcomes in the main group. Posterisan administration after sclerotherapy and dearterialization of hemorrhoids was characterized by earlier disappearance of symptoms and reduced complaints of postoperative pain, itching, discomfort, and blood in stool compared with the control group. Pathological reactions associated with the use of the drug were not identified. Conclusion. Additional use of posterisan (suppositories and ointment for rectal administration) in minimally invasive surgery for hemorrhoid disease grade II—III stabilizes early outcomes and significantly improves long-term results due to immune stimulation, potentiation of reparative and restorative processes.